Lenz Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
LENZ Therapeutics commercially launched VIZZ, its FDA-approved presbyopia eye drop, in the U.S. in August 2025, generating initial product sales while continuing to incur significant net losses.
NASDAQ
Lenz Therapeutics files its 10-K, outlining its focus on developing and commercializing LNZ100, a novel eye drop for presbyopia, with a PDUFA target action date set for August 8, 2025.
NASDAQ
Graphite Bio discontinues its gene editing programs, restructures operations, and enters into a merger agreement with LENZ Therapeutics, marking a significant strategic shift.